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Abstract
Objective—Functional movement and seizure disorders are still widely misunderstood and 
receive little public and academic attention. This is in stark contrast to their high prevalence and 
levels of associated disability. In an exploratory observational study, the authors examined whether 
the relative lack of media coverage of functional neurological disorders is in part due to 
misidentification in “human interest” news stories.
Methods—Thirteen recent news stories from high-impact English-language media outlets that 
portrayed patients with complex symptoms either attributed to other diagnoses or presented as 
medical mysteries were identified using online keyword searches. All selected news stories 
contained video or still images displaying relevant symptoms. Cases were categorized into 
movement disorders or seizure disorders and were then independently assessed by 10 respective 
expert raters. For each category, one story of a patient whose symptoms were due to a well-
recognized neurological disease was also included. Both the diagnostic category and the respective 
confidence level were reported by each rater for each case. The interrater agreement was 
calculated for each group of disorders.
Results—The raters confirmed almost unanimously that all presented news stories except the 
negative control cases portrayed misidentified functional movement or seizure disorders. The 
interrater agreement and average diagnostic confidence were high.
Conclusions—Functional neurological disorders are often wrongly considered a rare medical 
curiosity of the past. However, these findings suggest that, while they are largely absent from 
public discourse, they often appear in the news incognito, hiding in plain sight.
There is a reason why functional neurological disorder (FND), also known as conversion 
disorder and (in the past) hysteria, has not shed its mythology and stigma. Unlike other 
historically misunderstood illnesses, such as epilepsy or AIDS, FND cannot be detected 
using electroencephalography or immunoassays. Instead, routine laboratory and imaging 
findings are typically normal, so for large parts of the medical community and the public, 
FND is still considered an elusive, “medically unexplained” disorder, diagnosed by 
exclusion, almost indistinguishable from malingering. These assumptions, however, are 
wrong. Whether manifesting as a movement disorder or seizures, FND can be identified with 
confidence by physicians on the basis of phenotype-specific clinical signs (Table 1) (1–3). 
These tried and tested signs have been incorporated into validated sets of diagnostic criteria. 
In fact, when the diagnosis of FND is made by a specialist (in around 15% of all neurology 
presentations) it is almost invariably accurate and remains stable over time (4, 5).
This discrepancy is mirrored in a more general misunderstanding of FND by the public. 
Long marred by social stigma, FND has been a confusing and shameful diagnosis for many 
patients. Thus, it is not surprising that patients can be reluctant to accept a diagnosis of FND. 
Physicians, on the other hand, who are often uncertain about their diagnosis by exclusion, 
will often repeat tests and scans until a false positive or unrelated finding redirects the course 
of treatment. At this point alternative, less evidence-based explanations may be offered by 
well-meaning practitioners of different persuasions. Patients with FND can find themselves 
on tortured journeys through a multitude of clinics, and the eventual diagnosis of FND—
especially if explained poorly—is often met with skepticism. Sometimes these patient 
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journeys appear in social media, where misidentified FND is showcased unknowingly. On 
YouTube, for example, two-thirds of the most viewed movement disorder videos uploaded 
by patients have been found to show junctional movement disorders (6). Surprisingly, 
however, news articles portraying and discussing FND are a rarity. Are affected patients 
shunning the limelight, or are journalists and the public not interested in FND? A few high-
profile cases of misidentified FNDs in news stories (7–9) have suggested a different 
interpretation: FND is hiding in plain sight, wrongly attributed to an alternative neurological 
disorder or labeled a medical “mystery” (8). To test this hypothesis we conducted an 
informal observational study.
METHODS
News stories were identified by the study coordinators (S.P., T.R.N., J.S.) through 
nonsystematic online searches using Google’ s video search and the online search function of 
news outlets. Implementing a strictly formulated systematic search strategy was infeasible 
due to the vastness of online media content and the variability of terminology encountered in 
such articles. The following criteria were used to select appropriate news stories: English 
language; major media outlet; content available online; published within the last 5 years; 
available material (including video or still images) sufficiently detailed to offer independent 
experts an opportunity to make a diagnostic judgment; case not already subject to wide 
public debate; neurological symptoms portrayed likely to be functional based on positive 
criteria (1–3); functional (psychogenic) etiology not acknowledged. Ultimately, 13 news 
stories that fulfilled all criteria were selected. The news stories came from the following 
sources: BBC (N=4), CNN (N=3), FOX (N=1), Las Vegas Review-Journal (N=1), The 
Telegraph (N=1), ABC News (N=1), Coventry Telegraph (N=1), and The Guardian (N=1).
To test whether these news stories indeed portrayed unacknowledged or misidentified FND, 
they were presented to a group of expert raters. The news stories were split into two groups: 
seizures and movement disorders. One news story was featured in both categories (case 5 in 
seizure group and case 2 in movement disorders group), since both symptoms were reported 
and portrayed. For each category, a news story showing a relatively rare neurological 
disorder other than FND was also added as a negative control case to counteract the inherent 
rater bias of participating in a study on FND in media. These control cases were otherwise 
chosen using the same selection criteria (sources: FOX and KGW). Raters were told that 
there would be at least one news story featuring a neurological disorder other than FND to 
encourage critical consideration of competing etiologies.
Ten movement disorders specialists and ten epileptologists representing a broad field of 
clinical and research expertise were asked to participate in the study as expert raters. Each 
rater independently completed a form with instructions and a table including eight news 
stories (seven per group, including one case that had both movement disorder and seizures, 
plus one control case). Raters were asked to judge whether the symptoms seen in each news 
story were most likely related to a functional disorder or due to an alternative neurological 
disease such as primary dystonia or epilepsy. Information from the article text could also be 
considered. Since dual diagnosis is possible, the task was to decide which etiology was most 
likely to explain the symptoms to a large extent or completely and provide a dichotomous 
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answer. Raters were then asked to indicate their diagnostic confidence for each case on a 
numerical 0–10 confidence scale (0=no confidence, 10=absolutely confident). Lastly, raters 
were asked to freely report specific signs or features that influenced their diagnostic 
decisions in order to encourage decisions on the basis of identifiable positive clinical signs.
Although all patients were presumed to have given consent to be portrayed in publicly 
accessible media outlets, a re-diagnosis without face-to-face consultation, while clinically 
possible in some cases, is ethically problematic (9); therefore, we are not reporting the 
source details of the specific news stories. The original rating forms, including the sources of 
news stories (URL links), were made available to the journal editors and peer reviewers but 
are not referenced in this article. No clinically obtained patient data were used in this study, 
so ethics committee approval was not sought.
To calculate interrater agreement, Cohen’ s kappa (ͬ ) was calculated according to the Fleiss-
Cuzick extension (10) using StatsDirect statistical software (Cheshire, United Kingdom) and 
interpreted as poor, fair, moderate, good, or very good according to categorization by Landis 
and Koch (11).
RESULTS
News stories in the movement disorders category are summarized in Table 1. In six of the 
seven cases with presumed functional movement disorders, agreement among raters was 
100% with an average confidence rating of 9.3 out of 10. In one case, there was 
disagreement, with nine of 10 raters judging it to be a functional movement disorder with an 
average confidence rating of 7.8/10. The negative control (case 8) was unanimously 
identified as “organic” (mean confidence rating, 9.5). The overall interrater agreement for 
the movement disorders category including the control case was ͬ=0.89 (very good; 95% 
CI=0.79–1.00, p<0.0001).
News stories in the seizure category are summarized in Table 2. In five of the seven cases 
with presumed dissociative attacks, agreement among raters was 100% with an average 
confidence rating of 8.9 out of 10. In two of the cases, there was some disagreement, with 
nine of 10 raters judging cases 1 and 6 to be a manifestation of FND, with average 
confidence ratings of 8.6 and 5.7, respectively. The negative control (case 8) was 
unanimously identified as epileptic (mean confidence rating, 8.5). The overall interrater 
agreement for the seizure category including the control case was ͬ=0.80 (very good; 95% 
CI=0.70–0.91, p<0.0001).
DISCUSSION
Our study identified 13 highly probable cases of FND in news media stories that were not 
recognized as such; 11 of these cases were reported as other medical conditions. Cases were 
divided into two categories (seizures and movement disorders) and presented to raters along 
with one negative control case to counteract bias. In both groups, raters confidently and 
mostly unanimously judged that the presentations were indeed best explained by FND and 
not, as often suggested in the news stories, neurological symptoms caused by diseases such 
as Lyme disease or epilepsy.
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Dissociative (non-epileptic) seizures and functional movement disorders are common forms 
of FND. The reliability of video-based remote diagnosis has been investigated for both 
disorders. Experienced epileptologists can correctly identify dissociative seizures in about 
85% of cases from video alone (12, 13). The more experience physicians have with 
dissociative seizures, the higher the rate of correct diagnosis via video (14). The diagnosis of 
functional movement disorders is based on positive clinical features such as distractibility, 
inconsistency, and incongruence with other neurological diseases and can be aided by 
phenotype-specific signs such as Hoover’ s sign or tremor entrainment (1, 3). Interrater 
agreement on video-based diagnosis has been variable and appears to be dependent on the 
difficulty of cases (15,16). However, as yet there is no laboratory test to serve as a gold 
standard and validate clinical judgment of experts (17). Our specifically preselected videos 
and articles can be assumed to represent particularly clear-cut cases of functional movement 
disorders, which probably explains the high interrater agreement in our study. Similarly, a 
study in which experts rated functional movement disorders in popular YouTube videos 
yielded very high interrater agreement (6).
There are various potential reasons for the misrepresentation of FND in news media. A 
major factor is probably the high rate of underdiagnosis of these disorders by physicians. 
Around 30% of patients referred to epilepsy centers with refractory seizures do not have 
epilepsy, and a large portion of those have dissociative seizures (18). The high rate of 
misdiagnosis is furthermore evident in the exceptionally long diagnostic latency of about 5–
10 years for those who are eventually diagnosed correctly as experiencing dissociative 
seizures (18, 19). While there are no studies quantifying the rate of misdiagnosis of 
functional movement disorders as other neurological diseases, FNDs in general regularly 
figure in statistics of misdiagnoses of other neurological disorders. In a study of 110 patients 
misdiagnosed as having multiple sclerosis, the underlying reason was FND in 11% and 
fibromyalgia in 15% (20). In stroke medicine, FNDs account for 28%—47% of all 
retrospectively recognized stroke mimics mistakenly treated with intravenous tissue 
plasminogen activator (21, 22). Naturally, when FND is missed by neurologists who 
typically worry more about missing structural than functional disorders, neither patients nor 
journalists should be expected to identify it in human interest stories. In addition, patients 
with unresolved diagnoses are arguably more likely to seek redress or validation through the 
media.
Even when FND is correctly recognized by a physician, patients can often be left unsure or 
unaccepting about the essence and certainty of their diagnosis (23). Neurologists often hold 
negative views on FND (24), find little about FND in their textbooks or training curricula 
(25), have concerns about diagnostic certainty or malingering (26), and often assume a pre-
emptively defensive stance when communicating the diagnosis (27). Patients are often 
presented with outmoded or overly narrow versions of psychosomatic models that are liable 
to be interpreted in offensive terms (28). Many wonder why there is no radiologic or 
laboratory proof of diagnosis, and some hold on to strong views about alternative diagnoses 
(23, 29). Crucially, physicians and therapists need to help patients and the public understand 
the central role of positive clinical signs in the diagnostic process (1–3). High-tech brain 
scans and novel antibodies make for impressive headlines, but they are not how movement 
disorders or seizures are primarily diagnosed. Neurologists need to communicate the 
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reliability of clinical signs and syndrome classifications in order to get across why FND is 
not a dustbin diagnosis, but a common, well-recognized and potentially treatable condition. 
Finally, the lack of established treatment services in many places might also explain why 
FND patients are prone to seek help and validation online or through news media (6). 
Historically, there has been a distinct absence of positive or neutral public awareness of 
FND, which may underlie some of these issues and is certainly a factor on its own. 
Thankfully this is beginning to change.
FND Hope (www.fndhope.org) and FND Action (www.fndaction.org.uk) are examples of 
newly established patient-led organizations promoting awareness of the disorder and its 
treatment. In a few rare instances, individuals with FND have been profiled in informed and 
positive news stories (30–32). The Movement Disorders Society has a new Functional 
Movement Disorders Study Group to aid international collaboration, and the International 
League Against Epilepsy has an active Psychogenic Non-Epileptic Seizures Task Force. The 
Functional Neurological Disorder Society will be inaugurated shortly, providing a platform 
and resource for all healthcare professionals, scientists, students, and members of the lay 
public who are interested in FND (www.fndsociety.org). Lifting the stigma and mystery 
surrounding FND will require a shift in attitudes, both medical and societal. Psychiatrists, 
neurologists, psychologists, physiotherapists, occupational therapists, and everyone else who 
is involved in caring for patients with FND need to work together toward improving health 
care provision for this common and disabling disorder. The medical community needs to 
engage in interdisciplinary and collaborative publicity efforts with patients, artists, 
journalists, and policy makers in order to break the cycle of misconceptions and 
misrepresentation and lead FND back out of hiding.
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TABLE 1.
Movement disorders portrayed in selected news media storiesa
Case Year Age (years)/sex
Diagnosis in news 
story
Rated functional Rated “organic”
Selected positive signsc
Raters (%) Mean 
confidenceb
Raters (%) Mean 
confidenceb
1 2016 36/Male Dystonia, dystonic 
storms
100 9.4 0 — Asynchronous clonic movements; rhythmic pelvic movements; 
variable tremulous movement; abnormal movements seem 
activated by a light tactile stimulus
2 2012 16/Female Lyme disease 100 9.9 0 — Noneconomic posture while walking; extreme variability; 
incongruence; attention modulation
3 2016 NA/Male Tremor, medication-
induced
100 9.9 0 — Whack-a-mole sign; tremor in different directions; volitional 
control to stop tremor
4 2017 27/Female Dystonia, drug-
induced
100 9.7 0 — Lip-pulling sign; huffing and puffing sign; crouched gait; mixed 
and incongruent phenomenology
5 2017 NA/Female Unnamed condition 100 7.9 0 — Huffing and puffing sign; clenching fist in absence of spasticity/
parkinsonism; gasping for air but not during speech; dragging gait; 
bilateral fixed ankle posturing with inversion; fixed dystonia
6 2013 41/Female Dystonia 100 9.2 0 — “Other Babinski” sign; lip-pulling sign; symmetry of platysma 
contraction
7 2016 NA/Female Surgery-induced 
Tremor
90 7.8 10 8.0 Variability of frequency and amplitude of tremor; pause with 
ballistic movement; distractible
8d 2015 35/Male Dystonia 0 — 100 9.5 Striatal postural deformities; patterned dystonic postures; scoliotic dystonic trunk abnormality
aNA=information not available.
b0–10 confidence scale (0=no confidence, 10=absolutely confident).
c
Raters were prompted to report any signs that influenced their diagnostic decision; selected signs identified by one or more raters are reported.
dControl case.
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TABLE 2.
Seizures portrayed in selected news media storiesa
Case Year Age (years)/sex
Diagnosis in news 
story
Rated psychogenic Rated “organic”
Selected positive signsc
Raters (%) Mean 
confidenceb
Raters (%) Mean 
confidenceb
1 2017 19/Female Epilepsy 90 8.6 10 6.0 Eye closure; back arching; eyes roll up; high variability of 
events; rapid recovery
2 2015 35/Female Epilepsy 100 9.4 0 — Eyes closed; waxing/waning; body thrusting; movements mild 
with no suggestion of increased tone
3 2016 23/Male Unknown disease 100 7.6 0 — Side-to-side head shaking; forced eye closure; rolling side to 
side; markedly variable manifestations; semipurposeful 
movements
4 2015 21/Female Clinically dead due to 
POTS
100 9.4 0 — Buildup of the event with hyperventilation; prolonged floppy 
unresponsiveness
5 2012 16/Female Seizures due to Lyme 
disease
100 9.5 0 — Ictal crying; asynchronous low-amplitude tremulous shoulder 
movements
6 2016 16/Female Seizures 90 5.7 10 2.0 Sudden loss of consciousness with intense emotion; prolonged 
unresponsiveness; no apparent premonitory symptoms or signs
7 2015 21/Female Seizures due to mast 
cell disease
100 8.4 0 — Closed eyes; asynchronous side-to-side head and shoulder 
movements
8d 2016 10/Female Seizures 0 — 100 8.5 Eyes open; eye deviation to the side; rhythmic, synchronous tonic-clonic movements
a
POTS=postural orthostatic tachycardia syndrome.
b0–10 confidence scale (0=no confidence, 10=absolutely confident).
c
Raters were prompted to report any signs that influenced their diagnostic decision; selected signs identified by one or more raters are reported.
dControl case.
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